Ellipsys Fistula for Hemodialysis Access

NCT ID: NCT03828253

Last Updated: 2019-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-08-27

Study Completion Date

2021-08-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To report the outcomes of patients having percutaneous proximal radial artery fistula creation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study would like to enroll up to 100 patients without age, gender-based, race and ethnicity enrollment restrictions for adults over 18 years of age. Women of child bearing potential are not excluded. If a pregnant patient required, an arteriovenous fistula for hemodialysis an Ellipsys® fistula would be an option. The Investigator would like to consent previous Ellipsys® patients with appropriate medical records so that the Investigator may capture participants data for outcomes reporting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ESRD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient age \> 18 years or older
* Diagnosed with ESRD or chronic kidney disease requiring dialysis or anticipating start of dialysis
* Adjacent vein diameter of \> 2.0 mm at target anastomosis site and confirmed clinically significant outflow
* Arterial lumen diameter of \> 2.0 mm at target anastomosis site
* Adequate collateral arterial perfusion: Barbeau test grade A through C
* Radial artery -adjacent vein proximity \< 1.5 mm measured lumen edge-to-lumen edge via ultrasound

Exclusion Criteria

* Target vessel that are \< 2mm is diameter
* Distance between the target artery and vein \> 1.5 mm
* Edema of the upper extremity on the ipsilateral side
* Barbeau test grade D
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Richmond Vascular Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey Hull, MD

Role: PRINCIPAL_INVESTIGATOR

Richmond Vascular Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Richmond Vascular Center

North Chesterfield, Virginia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tricia Eichenlaub, RN

Role: CONTACT

804-864-8346

Brittani Lewis

Role: CONTACT

804-864-8346

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tricia Eichenlaub, RN

Role: primary

804-864-8346

Brittani Lewis

Role: backup

804-864-8346

References

Explore related publications, articles, or registry entries linked to this study.

Hull J, Deitrick J, Groome K. Maturation for Hemodialysis in the Ellipsys Post-Market Registry. J Vasc Interv Radiol. 2020 Sep;31(9):1373-1381. doi: 10.1016/j.jvir.2020.03.001. Epub 2020 Aug 14.

Reference Type DERIVED
PMID: 32800660 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

pAVF 1.0

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.